PTH receptor agonists
- Intermittent PTH signaling builds bone
- Teriparatide/abaloparatide: very high fracture risk
- Palopegteriparatide replaces PTH in hypopara
- Osteoporosis courses are time-limited
- Follow anabolic therapy with antiresorptive
- Hypercalcemia can occur
- Use differs dramatically by indication
Class at a glance
- Intermittent PTH signaling builds bone
Practical pearls
- Palopegteriparatide replaces PTH in hypopara
Clinical role
- Follow anabolic therapy with antiresorptive
- Use differs dramatically by indication
Safety / monitoring
- Teriparatide/abaloparatide: very high fracture risk
- Osteoporosis courses are time-limited
- Hypercalcemia can occur
Self-check
- What should follow anabolic osteoporosis therapy?
Antiresorptive therapy. - Which PTH agent replaces PTH in hypoparathyroidism?
Palopegteriparatide.
Drugs in this class (2)
PTH receptor agonists prescription history
Animated chart of estimated U.S. prescriptions per year, Osteoporosis meds (1975–2026). PTH analog highlighted from 2003.
All drug classes · Open PTH receptor agonists in the interactive console ↗